Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy

作者：Meixi Hao, Siyuan Hou, Weishuo Li, Kaiming Li, Lingjing Xue, Qifan Hu, Lulu Zhu, Yue Chen, Hongbin Sun, Caoyun Ju, Can Zhang · 发表于：Science Translational Medicine · 年份：2020 · DOI：10.1126/scitranslmed.aaz6667 · 被引用次数：180 · 研究领域：CAR-T cell therapy research、Cancer Research and Treatments、Neuroblastoma Research and Treatments

T cells or human chimeric antigen receptor T cells, resulted in superior antitumor efficacy in mouse models of melanoma and glioblastoma. Glioblastoma was completely eradicated in three of the five mice receiving surface anchor-engineered chimeric antigen receptor T cells, whereas mice in other treatment groups survived no more than 64 days. Moreover, the administration of engineered T cells showed no obvious systemic side effects. These cell-surface anchor-engineered T cells hold translational potential because of their simple generation and their safety profile.